Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,220,493 papers from all fields of science
Search
Sign In
Create Free Account
FR 901469
Known as:
FR901469
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Depsipeptides
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Further enhancement of FR901469 productivity by co-overexpression of cpcA, a cross-pathway control gene, and frbF in fungal sp. No. 11243.
M. Matsui
,
Tatsuya Yokoyama
,
+4 authors
Takashi Shibata
Journal of Bioscience and Bioengineering
2017
Corpus ID: 28011267
2006
2006
Novel Antifungal Antibiotic from an Unidentified Fungus No . 11243 I . Taxonomy , Fermentation , Isolation , Physico-chemical Properties and Biological Properties
A. Fujie
,
T. Iwamoto
,
+8 authors
M. Okuhara
2006
Corpus ID: 18525129
FR901469 is a novel antifimgal antibiotic produced by an unidentified fungus No.1 1243. This compound was isolated from the…
Expand
2001
2001
FR901469, a novel antifungal antibiotic from an unidentified fungus No. 11243. III. Structure determination.
A. Fujie
,
H. Muramatsu
,
S. Yoshimura
,
M. Hashimoto
,
N. Shigematsu
,
S. Takase
Journal of antibiotics (Tokyo. )
2001
Corpus ID: 38544169
A novel antifungal antibiotic, FR901469, was isolated from an unidentified fungus No. 11243. It is a water-soluble 40-membered…
Expand
2001
2001
Novel amidine conjugates of the ornithine moiety of the macrocyclic antifungal lipopeptidolactone FR901469.
D. Barrett
,
A. Tanaka
,
E. Watabe
,
K. Maki
,
F. Ikeda
Journal of antibiotics (Tokyo. )
2001
Corpus ID: 13955367
moiety of 1.8) We have also reported novel methodology for the synthesis of the amide analog of 19) and non-ornithinecontaining…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE